Grace Therapeutics Inc stock is traded at $1.87, with a volume of 35,033. It is up +5.06% in the last 24 hours and down -9.44% over the past month. Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.
Previous Close:
$1.78
Open:
$1.85
24h Volume:
35,033
Relative Volume:
0.24
Market Cap:
$39.34M
Revenue:
-
Net Income/Loss:
-$7.79M
P/E Ratio:
-
EPS:
-$0.4802
Net Cash Flow:
-$8.94M
1W Performance:
-3.61%
1M Performance:
-9.44%
6M Performance:
-21.10%
1Y Performance:
-38.49%
1-Day Range:
$1.83$1.90
1-Week Range:
$1.70$2.01
52-Week Range:
$1.67$5.18
Grace Therapeutics Inc Stock (GRCE) Company Profile
Name
Grace Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
609-322-1602Address
103 CARNEGIE CENTER, PRINCETON, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS